C4X-6746

C4X-6746 is a **preclinical oral small-molecule activator of nuclear factor erythroid 2-related factor 2** designed to disrupt the **Kelch-like ECH-associated protein 1 and Nrf2 protein-protein interaction**, thereby releasing Nrf2 from Keap1-mediated repression and increasing transcription of cytoprotective antioxidant and anti-inflammatory genes. The program originated at **C4X Discovery** and was included in the company's **NRF2 Activator** partnership with **AstraZeneca** focused on chronic inflammatory and respiratory diseases. Publicly described intended indications include **inflammatory bowel disease** and **chronic obstructive pulmonary disease**, with reported activity in preclinical rat colitis models. No nonproprietary name or approved brand name has been publicly identified.